Myeloproliferative neoplasms (MPNs) encompass a heterogeneous group of chronic, clonal haematopoietic stem cell neoplasms that harbor the propensity to undergo leukaemic transformation. Epidemiological data on MPNs especially pertaining to non-Caucasian populations is limited, and the molecular pathogenesis of MPN remains unclear. Although the discovery of MPN driver mutations in JAK2, MPL and CALR in the last decade has revolutionised disease management, the mutations are not specific for any MPN subtype. The management of MPNs is further challenged by substantial genetic and phenotypic heterogeneity that exist between and within MPN subtypes as well as other myeloid diseases. In this review, we focus on the classical Philadelphia chromosome (Ph)-negative MPNs – polycythaemia vera (PV), essential thrombocythaemia (ET), and primary myelofibrosis (PMF); providing an overview on the current understanding of the disease at a clinical and molecular standpoint while discussing the present challenges and future opportunities in the management of MPNs.

1. Dameshek, W. (1951). Some speculations on the myeloproliferative syndromes. Blood, 6(4), 374.
2. Swerdlow, S. H., Campo, E., Harris, N. L., Jaffe, E. S., Pileri, S. A., Stein, H., et al. (2017). WHO classification of tumours of haematopoietic and lymphoid tissues (Revised 4th ed.). International Agency for Research on Cancer.
3. Titmarsh, G. J., Duncombe, A. S., McMullin, M. F., O’Rorke, M., Mesa, R., De Vocht, F., et al. (2014). How common are myeloproliferative neoplasms? A systematic review and meta-analysis. American Journal of Hematology, 89(6), 581–587.
4. Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J., et al. (2005). Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7(4), 387–397.
5. Tefferi, A., & Vardiman, J. W. (2008). Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia, 22(1), 14–22.
6. Anderson, L. A., Duncombe, A. S., Hughes, M., Mills, M. E., Wilson, J. C., & McMullin, M. F. (2012). Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms. American Journal of Hematology, 87(2), 175–182.
7. Deadmond, M. A., & Smith-Gagen, J. A. (2015). Changing incidence of myeloproliferative neoplasms: Trends and subgroup risk profiles in the USA, 1973–2011. Journal of Cancer Research and Clinical Oncology, 141(12), 2131–2138.
8. Heppner, J., Nguyen, L. T., Guo, M., Naugler, C., & Rashid-Kolvear, F. (2019). Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada. BMC Research Notes, 12(1), 286.
9. Roaldsnes, C., Holst, R., Frederiksen, H., & Ghanima, W. (2017). Myeloproliferative neoplasms: Trends in incidence, prevalence and survival in Norway. European Journal of Haematology, 98(1), 85–93.
10. Hultcrantz, M., Ravn Landtblom, A., Andréasson, B., Samuelsson, J., Dickman, P. W., Kristinsson, S. Y., et al. (2020). Incidence of myeloproliferative neoplasms—Trends by subgroup and age in a population-based study in Sweden. Journal of Internal Medicine, 287(4), 448–454.
11. Lim, Y., Lee, J. O., & Bang, S. M. (2016). Incidence, survival and prevalence statistics of classical myeloproliferative neoplasm in Korea. Journal of Korean Medical Science, 31(10), 1579–1585.
12. Ebid, G. T., Ghareeb, M., Salaheldin, O., & Kamel, M. M. (2015). Prevalence of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients. International Journal of Clinical and Experimental Pathology, 8(9), 11555–11559.
13. Benmoussa, A., Dehbi, H., Fehri, S., Quessar, A., & Nadifi, S. (2011). JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: Contribution, diagnosis and therapeutic prospects. Pathologie-Biologie, 59(4), e89–e92.
14. De Kock, A., & Booysen, C. (2016). Screening for calreticulin mutations in a cohort of patients suspected of having a myeloproliferative neoplasm. South African Medical Journal, 106(12), 1260–1262.
15. Sazawal, S., Bajaj, J., Chikkara, S., Jain, S., Bhargava, R., Mahapatra, M., et al. (2010). Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders. The Indian Journal of Medical Research, 132, 423–427.
16. Lieu, C. H., Shen, Y. J., Lai, W. C., Tsai, W. H., & Hsu, H. C. (2010). Prevalence of MPL W515L/K mutations in Taiwanese patients with Philadelphia-negative chronic myeloproliferative neoplasms. Journal of the Chinese Medical Association, 73(10), 530–532.
17. Lieu, C. H., Wu, H. S., Hon, Y. C., Tsai, W. H., Yang, C. F., Wang, C. C., et al. (2008). Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders. Internal Medicine Journal, 38(6), 422–426.
18. Guo, H., Chen, X., Tian, R., Chang, J., Li, J., Tan, Y., et al. (2015). Frequencies, laboratory features, and granulocyte activation in Chinese patients with CALR-mutated myeloproliferative neoplasms. PLOS ONE, 10(9), e0138250.
19. Harrison, C. N., Koschmieder, S., Foltz, L., Guglielmelli, P., Flindt, T., Köhler, M., et al. (2017). The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: Results from the international MPN Landmark survey. Annals of Hematology, 96(10), 1653–1665.
20. Mesa, R. A., Kantarjian, H., Tefferi, A., Dueck, A., Levy, R., Vaddi, K., et al. (2011). Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: Performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer, 117(21), 4869–4877.
21. Tefferi, A. (2014). Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 89(9), 915–925.
22. Cervantes, F., Passamonti, F., & Barosi, G. (2008). Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia, 22(5), 905–914.
23. Kvasnicka, H. M., & Thiele, J. (2006). The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia vera. Seminars in Thrombosis and Hemostasis, 32(4 Pt 2), 362–371.
24. Finazzi, G., Vannucchi, A. M., & Barbui, T. (2018). Prefibrotic myelofibrosis: Treatment algorithm 2018. Blood Cancer Journal, 8(11), 104.
25. Mesa, R. A., Li, C. Y., Ketterling, R. P., Schroeder, G. S., Knudson, R. A., & Tefferi, A. (2005). Leukemic transformation in myelofibrosis with myeloid metaplasia: A single-institution experience with 91 cases. Blood, 105(3), 973–977.
26. Crisa, E., Venturino, E., Passera, R., Prina, M., Schinco, P., Borchiellini, A., et al. (2010). A retrospective study on 226 polycythemia vera patients: Impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs. Annals of Hematology, 89(7), 691–699.
27. Wolanskyj, A. P., Schwager, S. M., McClure, R. F., Larson, D. R., & Tefferi, A. (2006). Essential thrombocythemia beyond the first decade: Life expectancy, long-term complication rates, and prognostic factors. Mayo Clinic Proceedings, 81(2), 159–166.
28. Barbui, T., Thiele, J., Passamonti, F., Rumi, E., Boveri, E., Ruggeri, M., et al. (2011). Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study. Journal of Clinical Oncology, 29(23), 3179–3184.
29. Nangalia, J., Grinfeld, J., & Green, A. R. (2016). Pathogenesis of myeloproliferative disorders. Annual Review of Pathology: Mechanisms of Disease, 11, 101–126.
30. Adamson, J. W., Fialkow, P. J., Murphy, S., Prchal, J. F., & Steinmann, L. (1976). Polycythemia vera: Stem-cell and probable clonal origin of the disease. New England Journal of Medicine, 295(17), 913–916.
31. Ishii, T., Bruno, E., Hoffman, R., & Xu, M. (2006). Involvement of various hematopoietic-cell lineages by the JAK2 V617F mutation in polycythemia vera. Blood, 108(9), 3128–3134.
32. Jamieson, C. H. M., Gotlib, J., Durocher, J. A., Chao, M. P., Mariappan, M. R., Lay, M., et al. (2006). The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proceedings of the National Academy of Sciences of the United States of America, 103(16), 6224–6229.
33. Delhommeau, F., Dupont, S., Tonetti, C., Massé, A., Godin, I., Le Couédic, J. P., et al. (2007). Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood, 109(1), 71–77.
34. James, C., Ugo, V., Le Couédic, J. P., Staerk, J., Delhommeau, F., Lacout, C., et al. (2005). A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434(7037), 1144–1148.
35. Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., et al. (2005). Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. The Lancet, 365(9464), 1054–1061.
36. Kralovics, R., Passamonti, F., Buser, A. S., Teo, S. S., Tiedt, R., Passweg, J. R., et al. (2005). A gain-of-function mutation of JAK2 in myeloproliferative disorders. New England Journal of Medicine, 352(17), 1779–1790.
37. Scott, L. M., Tong, W., Levine, R. L., Scott, M. A., Beer, P. A., Stratton, M. R., et al. (2007). JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. New England Journal of Medicine, 356(5), 459–468.
38. Pardanani, A., Lasho, T. L., Finke, C., Hanson, C. A., & Tefferi, A. (2007). Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia, 21(9), 1960–1963.
39. Passamonti, F., Elena, C., Schnittger, S., Skoda, R. C., Green, A. R., Girodon, F., et al. (2011). Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood, 117(10), 2813–2816.
40. Grisouard, J., Li, S., Kubovcakova, L., Rao, T. N., Meyer, S. C., Lundberg, P., et al. (2016). JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis. Blood, 128(6), 839–851.
41. Nangalia, J., & Green, A. R. (2017). Myeloproliferative neoplasms: From origins to outcomes. Blood, 130(23), 2475–2483.
42. Pardanani, A. D., Levine, R. L., Lasho, T., Pikman, Y., Mesa, R. A., Wadleigh, M., et al. (2006). MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients. Blood, 108(10), 3472–3476.
43. Pikman, Y., Lee, B. H., Mercher, T., McDowell, E., Ebert, B. L., Gozo, M., et al. (2006). MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Medicine, 3(7), e270.
44. Defour, J. P., Chachoua, I., Pecquet, C., & Constantinescu, S. N. (2015). Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: Implications for myeloproliferative neoplasms. Leukemia.
45. Defour, J. P., Itaya, M., Gryshkova, V., Brett, I. C., Pecquet, C., Sato, T., et al. (2013). Tryptophan at the transmembrane–cytosolic junction modulates thrombopoietin receptor dimerization and activation. Proceedings of the National Academy of Sciences, 110(7), 2540–2545.
46. Ding, J., Komatsu, H., Wakita, A., Kato-Uranishi, M., Ito, M., Satoh, A., et al. (2004). Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene. Blood, 103(11), 4198–4200.
47. Ding, J., Komatsu, H., Iida, S., Yano, H., Kusumoto, S., Inagaki, A., et al. (2009). The Asn505 mutation of the c-MPL gene induces autonomous homodimerization of the c-Mpl protein. Blood, 114(15), 3325–3328.
48. Cabagnols, X., Favale, F., Pasquier, F., Messaoudi, K., Defour, J. P., Ianotto, J. C., et al. (2016). Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood, 127(3), 333–342.
49. Nangalia, J., Massie, C. E., Baxter, E. J., Nice, F. L., Gundem, G., Wedge, D. C., et al. (2013). Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. New England Journal of Medicine, 369(25), 2391–2405.
50. Klampfl, T., Gisslinger, H., Harutyunyan, A. S., Nivarthi, H., Rumi, E., Milosevic, J. D., et al. (2013). Somatic mutations of calreticulin in myeloproliferative neoplasms. New England Journal of Medicine, 369(25), 2379–2390.
51. Elf, S., Abdelfattah, N. S., Chen, E., Perales-Paton, J., Rosen, E. A., Ko, A., et al. (2016). Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation. Cancer Discovery, 6(4), 368–381.
52. Chachoua, I., Pecquet, C., El-Khoury, M., Nivarthi, H., Albu, R. I., Marty, C., et al. (2016). Thrombopoietin receptor activation by myeloproliferative neoplasm–associated calreticulin mutants. Blood, 127(10), 1325–1335.
53. Marty, C., Pecquet, C., Nivarthi, H., El-Khoury, M., Chachoua, I., Tulliez, M., et al. (2016). Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood, 127(10), 1317–1324.
54. Balligand, T., Achouri, Y., Pecquet, C., Chachoua, I., Nivarthi, H., Marty, C., et al. (2016). Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin. Leukemia, 30(8), 1775–1778.
55. Shide, K., Kameda, T., Yamaji, T., Sekine, M., Inada, N., Kamiunten, A., et al. (2017). Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib. Leukemia, 31(5), 1136–1144.
56. Kaushansky, K. (2005). The molecular mechanisms that control thrombopoiesis. Journal of Clinical Investigation, 115(12), 3339–3347.
57. Tefferi, A., & Vannucchi, A. M. (2017). Genetic risk assessment in myeloproliferative neoplasms. Mayo Clinic Proceedings, 92(8), 1283–1290.
58. Grinfeld, J., Nangalia, J., & Green, A. R. (2017). Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms. Haematologica, 102(1), 7–17.
59. Saliba, J., Hamidi, S., Lenglet, G., Langlois, T., Yin, J., Cabagnols, X., et al. (2013). Heterozygous and homozygous JAK2V617F states modeled by induced pluripotent stem cells. PLoS ONE, 8(9), e74257.
60. Vannucchi, A. M., Antonioli, E., Guglielmelli, P., Rambaldi, A., Barosi, G., Marchioli, R., et al. (2007). Clinical profile of homozygous JAK2 V617F mutation in patients with polycythemia vera or essential thrombocythemia. Blood, 110(3), 840–846.
61. Godfrey, A. L., Chen, E., Pagano, F., Silber, Y., Campbell, P. J., & Green, A. R. (2013). Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia. Haematologica, 98(5), 718–721.
62. Tefferi, A., Lasho, T. L., Schwager, S. M., Strand, J. S., Elliott, M., Mesa, R., et al. (2006). The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer, 106(3), 631–635.
63. Li, J., Kent, D. G., Godfrey, A. L., Manning, H., Nangalia, J., Aziz, A., et al. (2014). JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease. Blood, 123(20), 3139–3151.
64. Tiedt, R., Hao-Shen, H., Sobas, M. A., Looser, R., Dirnhofer, S., Schwaller, J., et al. (2008). Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood, 111(8), 3931–3939.
65. Akada, H., Akada, S., Hutchison, R. E., & Mohi, G. (2014). Loss of wild-type Jak2 allele enhances myeloid cell expansion and accelerates myelofibrosis in Jak2V617F knock-in mice. Leukemia, 28(8), 1627–1635.
66. Chang, Y.-C., Lin, H.-C., Chiang, Y.-H., Chen, C. G. S., Huang, L., Wang, W.-T., et al. (2017). Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms. Medical Oncology, 34(5).
67. Milosevic Feenstra, J. D., Nivarthi, H., Gisslinger, H., Leroy, E., Rumi, E., Chachoua, I., et al. (2016). Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood, 127(3), 325–332.
68. Zhang, S. J., Rampal, R., Manshouri, T., Patel, J., Mensah, N., Kayserian, A., et al. (2012). Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations associated with adverse outcome. Blood, 119(19), 4480–4485.
69. Rampal, R., Ahn, J., Abdel-Wahab, O., Nahas, M., Wang, K., Lipson, D., et al. (2014). Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proceedings of the National Academy of Sciences of the United States of America, 111(50), E5401–E5410.
70. O’Sullivan, J., & Mead, A. J. (2019). Heterogeneity in myeloproliferative neoplasms: Causes and consequences. Advances in Biological Regulation, 71, 55–68.
71. Jones, A. V., & Cross, N. C. P. (2013). Inherited predisposition to myeloproliferative neoplasms. Therapeutic Advances in Hematology, 4(4), 237–253.
72. Oddsson, A., Kristinsson, S. Y., Helgason, H., Gudbjartsson, D. F., Masson, G., Sigurdsson, A., et al. (2014). The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms. Leukemia, 28(6), 1371–1374.
73. Tapper, W., Jones, A. V., Kralovics, R., Harutyunyan, A. S., Zoi, K., Leung, W., et al. (2015). Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nature Communications, 6, 6691.
74. Trifa, A. P., Bănescu, C., Bojan, A. S., Voina, C. M., Popa, Ș., Vișan, S., et al. (2018). MECOM, HBS1L-MYB, THR-BARB, JAK2, and TERT polymorphisms defining genetic predisposition to myeloproliferative neoplasms: A study on 939 patients. American Journal of Hematology, 93(1), 100–106.
75. Harutyunyan, A. S., Giambruno, R., Krendl, C., Stukalov, A., Klampfl, T., Berg, T., et al. (2016). Germline RBBP6 mutations in familial myeloproliferative neoplasms. Blood, 127(3), 362–365.
76. Saliba, J., Saint-Martin, C., Di Stefano, A., Lenglet, G., Marty, C., Keren, B., et al. (2015). Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies. Nature Genetics, 47(10), 1131–1140.
77. Hinds, D. A., Barnholt, K. E., Mesa, R. A., Kiefer, A. K., Do, C. B., Eriksson, N., et al. (2016). Germline variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. Blood, 128(8), 1121–1128.
78. Ortmann, C. A., Kent, D. G., Nangalia, J., Silber, Y., Wedge, D. C., Grinfeld, J., et al. (2015). Effect of mutation order on myeloproliferative neoplasms. New England Journal of Medicine, 372(7), 601–612.
79. Nangalia, J., Nice, F. L., Wedge, D. C., Godfrey, A. L., Grinfeld, J., Thakker, C., et al. (2015). DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype. Haematologica, 100(11), e438–e442.
80. Haas, S., Trumpp, A., & Milsom, M. D. (2018). Causes and consequences of hematopoietic stem cell heterogeneity. Cell Stem Cell, 22(5), 627–638.
81. Dykstra, B., Kent, D., Bowie, M., McCaffrey, L., Hamilton, M., Lyons, K., et al. (2007). Long-term propagation of distinct hematopoietic differentiation programs in vivo. Cell Stem Cell, 1(2), 218–229.
82. Morita, Y., Ema, H., & Nakauchi, H. (2010). Heterogeneity and hierarchy within the most primitive hematopoietic stem cell compartment. Journal of Experimental Medicine, 207(6), 1173–1182.
83. Müller-Sieburg, C. E., Cho, R. H., Karlsson, L., Huang, J. F., & Sieburg, H. B. (2004). Myeloid-biased hematopoietic stem cells have extensive self-renewal capacity but generate diminished lymphoid progeny with impaired IL-7 responsiveness. Blood, 103(11), 4111–4118.
84. Yamamoto, R., Morita, Y., Ooehara, J., Hamanaka, S., Onodera, M., Rudolph, K. L., et al. (2013). Clonal analysis unveils self-renewing lineage-restricted progenitors generated directly from hematopoietic stem cells. Cell, 154(5), 1112–1126.
85. Carrelha, J., Meng, Y., Kettyle, L. M., Luis, T. C., Norfo, R., Alcolea, V., et al. (2018). Hierarchically related lineage-restricted fates of multipotent haematopoietic stem cells. Nature, 554(7690), 106–111.
86. Rodriguez-Fraticelli, A. E., Wolock, S. L., Weinreb, C. S., Panero, R., Patel, S. H., Jankovic, M., et al. (2018). Clonal analysis of lineage fate in native haematopoiesis. Nature, 553(7687), 212–216.
87. Pietras, E. M., Reynaud, D., Kang, Y. A., Carlin, D., Calero-Nieto, F. J., Leavitt, A. D., et al. (2015). Functionally distinct subsets of lineage-biased multipotent progenitors control blood production in normal and regenerative conditions. Cell Stem Cell, 17(1), 35–46.
88. Shin, J. Y., Hu, W., Naramura, M., & Park, C. Y. (2014). High c-Kit expression identifies hematopoietic stem cells with impaired self-renewal and megakaryocytic bias. Journal of Experimental Medicine, 211(2), 217–231.
89. Sanjuan-Pla, A., Macaulay, I. C., Jensen, C. T., Woll, P. S., Luis, T. C., Mead, A., et al. (2013). Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy. Nature, 502(7470), 232–236.
90. Adolfsson, J., Mansson, R., Buza-Vidas, N., Hultquist, A., Liuba, K., Jensen, C. T., et al. (2005). Identification of Flt3+ lympho-myeloid stem cells lacking erythromegakaryocytic potential: A revised road map for adult blood lineage commitment. Cell, 121(2), 295–306.*
91. Mead, A. J., & Mullally, A. (2017). Myeloproliferative neoplasm stem cells. Blood, 129(12), 1607–1616.
92. Lundberg, P., Takizawa, H., Kubovcakova, L., Guo, G., Hao-Shen, H., Dirnhofer, S., et al. (2014). Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F. Journal of Experimental Medicine, 211(11), 2213–2230.
93. Walkley, C. R., Olsen, G. H., Dworkin, S., Fabb, S. A., Swann, J., McArthur, G. A., et al. (2007). A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell, 129(6), 1097–1110.
94. Walkley, C. R., Shea, J. M., Sims, N. A., Purton, L. E., & Orkin, S. H. (2007). Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell, 129(6), 1081–1095.
95. Kim, Y. W., Koo, B. K., Jeong, H. W., Yoon, M. J., Song, R., Shin, J., et al. (2008). Defective Notch activation in microenvironment leads to myeloproliferative disease. Blood, 112(12), 4628–4638.
96. Wang, L., Zhang, H., Rodriguez, S., Cao, L., Parish, J., Mumaw, C., et al. (2014). Notch-dependent repression of miR-155 in the bone marrow niche regulates hematopoiesis in an NF-κB-dependent manner. Cell Stem Cell, 15(1), 51–65.
97. Fleischman, A. G., Aichberger, K. J., Luty, S. B., Bumm, T. G., Petersen, C. L., Doratotaj, S., et al. (2011). TNF-α facilitates clonal expansion of JAK2V617F-positive cells in myeloproliferative neoplasms. Blood, 118(24), 6392–6398.
98. Manshouri, T., Estrov, Z., Quintas-Cardama, A., Burger, J., Zhang, Y., Livun, A., et al. (2011). Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Research, 71(11), 3831–3840.
99. Drexler, H. G., Meyer, C., Zaborski, M., Uphoff, C. C., & Quentmeier, H. (1998). Growth-inhibitory effects of transforming growth factor-β1 on myeloid leukemia cell lines. Leukemia Research, 22(10), 927–938.
100. Kralovics, R., Guan, Y., & Prchal, J. T. (2002). Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Experimental Hematology, 30(3), 229–234.
101. Bogani, C., Ponziani, V., Guglielmelli, P., Desterke, C., Rosti, V., Bosi, A., et al. (2008). Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells, 26(8), 1920–1930.
102. Hasselbalch, H. C. (2013). The role of cytokines in the initiation and progression of myelofibrosis. Cytokine & Growth Factor Reviews, 24(2), 133–145.
103. Kleppe, M., Kwak, M., Koppikar, P., Riester, M., Keller, M., Bastian, L., et al. (2015). JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discovery, 5(3), 316–331.
104. Schepers, K., Pietras, E. M., Reynaud, D., Flach, J., Binnewies, M., Garg, T., et al. (2013). Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell, 13(3), 285–299.
105. Arranz, L., Sánchez-Aguilera, A., Martín-Pérez, D., Isern, J., Langa, X., Tzankov, A., et al. (2014). Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature, 512, 78–84.
106. Wen, Q. J., Yang, Q., Goldenson, B., Malinge, S., Lasho, T., Schneider, R. K., et al. (2015). Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nature Medicine, 21(12), 1473–1480.
107. Gianelli, U., Vener, C., Raviele, P. R., Savi, F., Somalvico, F., Calori, R., et al. (2007). VEGF expression correlates with microvessel density in Philadelphia chromosome-negative chronic myeloproliferative disorders. American Journal of Clinical Pathology, 128(6), 966–973.
108. Boveri, E., Passamonti, F., Rumi, E., Pietra, D., Elena, C., Arcaini, L., et al. (2008). Bone marrow microvessel density in chronic myeloproliferative disorders: A study of 115 patients with clinicopathological and molecular correlations. British Journal of Haematology, 140(2), 162–168.
109. Wang, X., Prakash, S., Lu, M., Tripodi, J., Ye, F., Najfeld, V., et al. (2012). Spleens of myelofibrosis patients contain malignant hematopoietic stem cells. Journal of Clinical Investigation, 122(11), 3888–3899.
110. Triviai, I., Ziegler, M., Bergholz, U., Oler, A. J., Stübig, T., Prassolov, V., et al. (2014). Endogenous retrovirus induces leukemia in a xenograft mouse model for primary myelofibrosis. Proceedings of the National Academy of Sciences of the United States of America, 111(23), 8595–8600.
111. Skov, V., Thomassen, M., Riley, C. H., Jensen, M. K., Bjerrum, O. W., Kruse, T. A., et al. (2012). Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis. Experimental Hematology, 40(9), 771–780.e19.
112. Vaidya, R., Gangat, N., Jimma, T., Finke, C. M., Lasho, T. L., Pardanani, A., et al. (2012). Plasma cytokines in polycythemia vera: Phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. American Journal of Hematology, 87(11), 1003–1005.
113. Adelman, E. R., Huang, H. T., Roisman, A., Olsson, A., Colaprico, A., Qin, T., et al. (2019). Aging human hematopoietic stem cells manifest profound epigenetic reprogramming of enhancers that may predispose to leukemia. Cancer Discovery.
114. Dykstra, B., Olthof, S., Schreuder, J., Ritsema, M., & de Haan, G. (2011). Clonal analysis reveals multiple functional defects of aged murine hematopoietic stem cells. Journal of Experimental Medicine, 208(13), 2691–2703.
115. Pang, W. W., Price, E. A., Sahoo, D., Beerman, I., Maloney, W. J., Rossi, D. J., et al. (2011). Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. Proceedings of the National Academy of Sciences of the United States of America, 108(50), 20012–20017.
116. Rossi, D. J., Bryder, D., Zahn, J. M., Ahlenius, H., Sonu, R., Wagers, A. J., et al. (2005). Cell intrinsic alterations underlie hematopoietic stem cell aging. Proceedings of the National Academy of Sciences of the United States of America, 102(26), 9194–9199.
117. Grover, A., Sanjuan-Pla, A., Thongjuea, S., Carrelha, J., Giustacchini, A., Gambardella, A., et al. (2016). Single-cell RNA sequencing reveals molecular and functional platelet bias of aged haematopoietic stem cells. Nature Communications, 7, 11075.
118. Chambers, S. M., Shaw, C. A., Gatza, C., Fisk, C. J., Donehower, L. A., & Goodell, M. A. (2007). Aging hematopoietic stem cells decline in function and exhibit epigenetic dysregulation. PLoS Biology, 5(8), e201.
119. Dupont, S., Massé, A., James, C., Teyssandier, I., Lecluse, Y., Larbret, F., et al. (2007). The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood, 110(3), 1013–1021.
120. Manzo, V. E., & Bhatt, A. S. (2015). The human microbiome in hematopoiesis and hematologic disorders. Blood, 126(3), 311–318.
121. Murphy, S., Peterson, P., Iland, H., & Laszlo, J. (1997). Experience of the Polycythemia Vera Study Group with essential thrombocythemia: A final report on diagnostic criteria, survival, and leukemic transition by treatment. Seminars in Hematology, 34(1), 29–39.
122. Jaffe, E. S., Harris, N. L., Stein, H., & Vardiman, J. W. (2001). Pathology and genetics of haematopoietic and lymphoid tissues. International Agency for Research on Cancer (IARC) Press.
123. Barbui, T., Thiele, J., Vannucchi, A. M., & Tefferi, A. (2015). Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer Journal, 5, e337.
124. Swerdlow, S. H., Campo, E., Harris, N. L., Jaffe, E. S., Pileri, S. A., Stein, H., et al. (2008). WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer (IARC) Press.
125. Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., et al. (2016). The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 127(20), 2391–2405.
126. Rumi, E., & Cazzola, M. (2017). Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood, 129(6), 680–692.
127. Grinfeld, J., Nangalia, J., Baxter, E. J., Wedge, D. C., Angelopoulos, N., Cantrill, R., et al. (2018). Classification and personalized prognosis in myeloproliferative neoplasms. New England Journal of Medicine, 379(15), 1416–1430.
128. Beer, P. A., Erber, W. N., Campbell, P. J., & Green, A. R. (2011). How I treat essential thrombocythemia. Blood, 117(5), 1472–1482.
129. Buhr, T., Hebeda, K., Kaloutsi, V., Porwit, A., Van der Walt, J., & Kreipe, H. (2012). European Bone Marrow Working Group trial on reproducibility of WHO criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica, 97(3), 360–365.
130. Wilkins, B. S., Erber, W. N., Bareford, D., Buck, G., Wheatley, K., East, C. L., et al. (2008). Bone marrow pathology in essential thrombocythemia: Interobserver reliability and utility for identifying disease subtypes. Blood, 111(1), 60–70.
131. Brousseau, M., Parot-Schinkel, E., Moles, M. P., Boyer, F., Hunault, M., & Rousselet, M. C. (2010). Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis. Histopathology, 56(6), 758–767.
132. Pozdnyakova, O., Rodig, S., Bhandarkar, S., Wu, K., Thiele, J., & Hasserjian, R. (2015). The importance of central pathology review in international trials: A comparison of local versus central bone marrow reticulin grading. Leukemia, 29(1), 241–244.
133. Tefferi, A. (2000). Myelofibrosis with myeloid metaplasia. New England Journal of Medicine, 342(17), 1255–1265.
134. McLornan, D. P., Mead, A. J., Jackson, G., & Harrison, C. N. (2012). Allogeneic stem cell transplantation for myelofibrosis in 2012. British Journal of Haematology, 157(4), 413–425.
135. Vannucchi, A. M., Barbui, T., Cervantes, F., Harrison, C., Kiladjian, J. J., Kroger, N., et al. (2015). Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines. Annals of Oncology, 26(Suppl 5), v85–v99.
136. Mullally, A., Bruedigam, C., Poveromo, L., Heidel, F. H., Purdon, A., Vu, T., et al. (2013). Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. Blood, 121(18), 3692–3702.
137. Harrison, C., Kiladjian, J. J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., et al. (2012). JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. New England Journal of Medicine, 366(9), 787–798.
138. Vannucchi, A. M., Kiladjian, J. J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., et al. (2016). Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica, 101(7), 821–829.
139. Vannucchi, A. M., Kiladjian, J. J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., et al. (2015). Ruxolitinib versus standard therapy for the treatment of polycythemia vera. New England Journal of Medicine, 372(5), 426–435.
140. Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., et al. (2012). A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. New England Journal of Medicine, 366(9), 799–807.
141. Barosi, G., Besses, C., Birgegård, G., Brière, J., Cervantes, F., Finazzi, G., et al. (2007). A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia. Leukemia, 21(2), 277–280.
142. Bose, P., & Verstovsek, S. (2017). Developmental therapeutics in myeloproliferative neoplasms. Clinical Lymphoma Myeloma and Leukemia, 17(Suppl), S43–S52.
143. Harrison, C. N., Vannucchi, A. M., Kiladjian, J. J., Al-Ali, H. K., Gisslinger, H., Knoops, L., et al. (2016). Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia, 30(8), 1701–1707.
144. Gupta, V., Verstovsek, S., Mesa, R. A., Gotlib, J. R., DiPersio, J. F., Catalano, J. V., et al. (2016). Long-term outcomes of ruxolitinib therapy in patients with myelofibrosis: 5-year update from COMFORT-I. Journal of Clinical Oncology, 34(15_suppl), 7012.
145. Deininger, M., Radich, J., Burn, T. C., Huber, R., Paranagama, D., & Verstovsek, S. (2015). The effect of long-term ruxolitinib treatment on JAK2 p.V617F allele burden in patients with myelofibrosis. Blood, 126(13), 1551–1554.
146. Bose, P., Gotlib, J., Harrison, C. N., & Verstovsek, S. (2018). SOHO state-of-the-art update and next questions: MPN. Clinical Lymphoma Myeloma and Leukemia, 18(1), 1–12.
147. Taylor, J., Xiao, W., & Abdel-Wahab, O. (2017). Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood, 130(4), 410–423.
148. Bacher, U., Shumilov, E., Flach, J., Porret, N., Joncourt, R., Wiedemann, G., et al. (2018). Challenges in the introduction of next-generation sequencing for diagnostics of myeloid malignancies into clinical routine use. Blood Cancer Journal, 8, 113.
149. Kuo, F. C., Mar, B. G., Lindsley, R. C., & Lindeman, N. I. (2017). The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice. Blood, 130(4), 433–439.
150. Zhang, J., Liu, J., Sun, J., Chen, C., Foltz, G., & Lin, B. (2014). Identifying driver mutations from sequencing data of heterogeneous tumors in the era of personalized genome sequencing. Briefings in Bioinformatics, 15(2), 244–255.
151. Glenn, T. C. (2011). Field guide to next-generation DNA sequencers. Molecular Ecology Resources, 11(5), 759–769.
152. Shiroguchi, K., Jia, T. Z., Sims, P. A., & Xie, X. S. (2012). Digital RNA sequencing minimizes sequence-dependent bias and amplification noise with optimized single-molecule barcodes. Proceedings of the National Academy of Sciences, 109(4), 1347–1352.
153. Sleep, J. A., Schreiber, A. W., & Baumann, U. (2013). Sequencing error correction without a reference genome. BMC Bioinformatics, 14, 367.
154. Rohlin, A., Wernersson, J., Engwall, Y., Wiklund, L., Björk, J., & Nordling, M. (2009). Parallel sequencing used in detection of mosaic mutations: Comparison with four diagnostic DNA screening techniques. Human Mutation, 30(6), 1012–1020.